IL300294A - Gene therapy using nucleic acid constructs containing methyl CPG-binding protein 2 (MECP2) promoter sequences - Google Patents

Gene therapy using nucleic acid constructs containing methyl CPG-binding protein 2 (MECP2) promoter sequences

Info

Publication number
IL300294A
IL300294A IL300294A IL30029423A IL300294A IL 300294 A IL300294 A IL 300294A IL 300294 A IL300294 A IL 300294A IL 30029423 A IL30029423 A IL 30029423A IL 300294 A IL300294 A IL 300294A
Authority
IL
Israel
Prior art keywords
nucleotide sequence
seq
nucleic acid
identity
acid construct
Prior art date
Application number
IL300294A
Other languages
English (en)
Hebrew (he)
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=77655525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL300294(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of IL300294A publication Critical patent/IL300294A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL300294A 2020-08-12 2021-08-11 Gene therapy using nucleic acid constructs containing methyl CPG-binding protein 2 (MECP2) promoter sequences IL300294A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063064431P 2020-08-12 2020-08-12
PCT/EP2021/072365 WO2022034130A1 (en) 2020-08-12 2021-08-11 Gene therapy using nucleic acid constructs comprising methyl cpg binding protein 2 (mecp2) promoter sequences

Publications (1)

Publication Number Publication Date
IL300294A true IL300294A (en) 2023-04-01

Family

ID=77655525

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300294A IL300294A (en) 2020-08-12 2021-08-11 Gene therapy using nucleic acid constructs containing methyl CPG-binding protein 2 (MECP2) promoter sequences

Country Status (19)

Country Link
US (1) US20230295657A1 (cg-RX-API-DMAC7.html)
EP (1) EP4196171A1 (cg-RX-API-DMAC7.html)
JP (1) JP7860958B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230044506A (cg-RX-API-DMAC7.html)
CN (1) CN116113441B (cg-RX-API-DMAC7.html)
AR (1) AR123206A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021325717A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023002374A2 (cg-RX-API-DMAC7.html)
CA (1) CA3188748A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023000419A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023000444A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP23016688A (cg-RX-API-DMAC7.html)
IL (1) IL300294A (cg-RX-API-DMAC7.html)
MX (1) MX2023001701A (cg-RX-API-DMAC7.html)
PE (1) PE20230914A1 (cg-RX-API-DMAC7.html)
PH (1) PH12023550145A1 (cg-RX-API-DMAC7.html)
TW (1) TWI902867B (cg-RX-API-DMAC7.html)
WO (1) WO2022034130A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202300378B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2022131322A1 (cg-RX-API-DMAC7.html) * 2020-12-17 2022-06-23
IL312340A (en) * 2021-10-28 2024-06-01 UCB Biopharma SRL Nucleic acid constructs, viral vectors and viral particles
GB202216168D0 (en) 2022-10-31 2022-12-14 UCB Biopharma SRL Route of administration
WO2024163823A1 (en) * 2023-02-02 2024-08-08 Shape Therapeutics Inc. Tissue-specific enhancers for regulating transcription
JP2026509301A (ja) * 2023-03-14 2026-03-17 ユーシービー バイオファルマ エスアールエル 遺伝子治療
CN121335978A (zh) * 2023-06-16 2026-01-13 舒泰神(北京)生物制药股份有限公司 一种人源MeCp2启动子及其用途
WO2025213097A1 (en) * 2024-04-05 2025-10-09 The Children's Hospital Of Philadelphia Novel gene therapy constructs for stxbp1 haploinsufficiency

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110045536A1 (en) * 2007-12-21 2011-02-24 Novartis Ag Mammalian expression vector
CN104583402A (zh) * 2012-05-16 2015-04-29 Rana医疗有限公司 用于调节mecp2表达的组合物和方法
GB201403684D0 (en) 2014-03-03 2014-04-16 King S College London Vector
CN114717264A (zh) * 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
AU2015349759B2 (en) * 2014-11-21 2022-01-06 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
JP6754361B2 (ja) * 2014-12-16 2020-09-09 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ ネブラスカ 若年型バッテン病のための遺伝子療法
CA3016314A1 (en) * 2016-03-02 2017-09-08 Julianne REIDERS Therapy for frontotemporal dementia
TWI601821B (zh) * 2016-04-15 2017-10-11 中央研究院 治療神經發展性疾病
WO2020081490A1 (en) * 2018-10-15 2020-04-23 Voyager Therapeutics, Inc. EXPRESSION VECTORS FOR LARGE-SCALE PRODUCTION OF rAAV IN THE BACULOVIRUS/Sf9 SYSTEM

Also Published As

Publication number Publication date
CO2023000444A2 (es) 2023-01-26
EP4196171A1 (en) 2023-06-21
JP7860958B2 (ja) 2026-05-18
AU2021325717A1 (en) 2023-03-02
CL2023000419A1 (es) 2023-07-21
CA3188748A1 (en) 2022-02-17
PE20230914A1 (es) 2023-06-02
TW202221018A (zh) 2022-06-01
US20230295657A1 (en) 2023-09-21
WO2022034130A1 (en) 2022-02-17
CN116113441A (zh) 2023-05-12
PH12023550145A1 (en) 2024-03-18
KR20230044506A (ko) 2023-04-04
BR112023002374A2 (pt) 2023-03-21
CN116113441B (zh) 2026-06-09
AR123206A1 (es) 2022-11-09
JP2023537980A (ja) 2023-09-06
ZA202300378B (en) 2024-04-24
TWI902867B (zh) 2025-11-01
ECSP23016688A (es) 2023-04-28
MX2023001701A (es) 2023-03-09

Similar Documents

Publication Publication Date Title
US20220331409A1 (en) Factor ix gene therapy
JP2023537980A5 (cg-RX-API-DMAC7.html)
IL273776B2 (en) Gene therapies for lysosomal disorders
JP7853952B2 (ja) Glut1発現のためのアデノ随伴ウイルスベクターおよびその使用
JP2017513861A (ja) 末梢性ニューロパチー及び運動ニューロン疾患の治療方法
US20250136981A1 (en) Compositions and methods comprising engineered short nuclear rna (snrna)
US20240318199A1 (en) Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders
JP2022541070A5 (cg-RX-API-DMAC7.html)
WO2019011817A1 (en) TREATMENT OF SPINAL AMYOTROPHY
KR20210096168A (ko) 신경퇴행성 질환을 위한 유전자 요법
CA3016314A1 (en) Therapy for frontotemporal dementia
EP3794131A1 (en) Raav vectors encoding of lysosomal beta-galactosidase (glb1) and cathepsin a
JP2025540074A (ja) 繰り返しエレメントの適切なパッケージングのためのアデノ随伴ウイルスベクター
AU2020278499A1 (en) Improved delivery of gene therapy vectors to retinal cells using a glycoside hydrolase enzyme
KR20230004617A (ko) 신경계 장애를 치료하기 위한 조성물 및 방법
CN117916365B (zh) 用于治疗结晶样视网膜变性的重组腺相关病毒载体
JP2017123840A (ja) グルコーストランスポーター1発現用アデノ随伴ウイルスベクター
EP4361278A1 (en) Composition and method for treating hemophilia b
JP2025515030A5 (cg-RX-API-DMAC7.html)
JP2024537167A5 (cg-RX-API-DMAC7.html)
TWI883636B (zh) 含有星狀細胞導向啟動子構築體之合成核酸及其使用方法
WO2025162449A1 (en) Compositions and methods for the treatment of heart disease
CN111093716A (zh) 用于治疗神经性疼痛的方法和组合物
RU2025132907A (ru) Нуклеиновая кислота, кодирующая белок, специфичный к vegf, полинуклеотидная кассета экспрессии и рекомбинантный аденоассоциированный вирус
RU2021117249A (ru) Модулирующие полинуклеотиды